



What is claimed is:

1. A method for preparing Compound 1



Compound 1,


the method comprising contacting a compound of Formula G



G


with an acid optionally in a solvent followed by neutralization with a base.

2. The method of claim 1, further comprising preparing a compound of formula G




G,

the method comprising contacting a compound of formula E



E


with a compound of formula F,



F


in the presence of palladium catalyst, a solvent and a base.

3. The method of claim 1, further comprising preparing a compound of formula E



E,


the method comprising contacting a compound of formula D



D


with a boron source and a palladium catalyst in the presence of a base in a solvent.

4. The method of claim 3, further comprising preparing a compound of formula D



D,


the method comprising contacting a compound of formula C



C


with EtNH₂ optionally in the presence of a base optionally in a solvent, followed by acidification.

5. The method of claim 4, further comprising preparing a compound of formula C



C,

the method comprising contacting a compound of formula B



B

with a base optionally in a solvent, followed by neutralization with an acid.

6. The method of claim 1, further comprising recrystallizing Compound 1, comprising the steps of:

(a) dissolving Compound 1 in a mixture of ethanol, water, and HCl at elevated temperature;

- (b) neutralizing the mixture with NH_4OH at elevated temperature; and
- (c) filtering the mixture.

7. The method of claim 1, further comprising recrystallizing Compound 1, comprising the steps of:

- (a) dissolving Compound 1 in a mixture of 1-propanol, water, and HCl ;
- (b) neutralizing the mixture with an aqueous base at elevated temperature; and
- (c) filtering the mixture.


8. The method of claims 6 or 7, further comprising :

- (a) treating the Compound 1 solution with activated carbon;
- (b) removing the activated carbon by filtration; prior to neutralization.

9. The method of claims 6 or 7, further comprising

- (a) treating the Compound 1 solution with a metal scavenger at elevated temperature;
- (b) removing the metal scavenger, prior to treating with activating carbon.

10. A solid form of Compound 1:




Compound 1.

11. The solid form of claim 10, wherein the solid form is one of Forms A-E.

12. A pharmaceutical composition comprising Compound 1, or a pharmaceutically acceptable salt, tautomer, isotopologue or stereoisomer thereof, and one or more pharmaceutically acceptable excipients or carriers, each independently selected from carboxymethyl cellulose, cellulose, lactose, magnesium stearate, starch, and stearic acid.


CLAIMS

1. A method for preparing Compound 1



Compound 1,


the method comprising contacting a compound of Formula G



G


with an acid optionally in a solvent followed by neutralization with a base.

2. The method of claim 1, further comprising preparing a compound of formula G




G,

the method comprising contacting a compound of formula E




E

with a compound of formula F,




in the presence of palladium catalyst, a solvent and a base.

3. The method of claim 1, further comprising preparing a compound of formula E




the method comprising contacting a compound of formula D




with a boron source and a palladium catalyst in the presence of a base in a solvent.

4. The method of claim 3, further comprising preparing a compound of formula D




the method comprising contacting a compound of formula C




with EtNH₂ optionally in the presence of a base optionally in a solvent, followed by acidification.

5. The method of claim 4, further comprising preparing a compound of formula C



C,

the method comprising contacting a compound of formula B



B

with a base optionally in a solvent, followed by neutralization with an acid.

6. The method of claim 1, further comprising recrystallizing Compound 1, comprising the steps of:

- (a) dissolving Compound 1 in a mixture of ethanol, water, and HCl at elevated temperature;
- (b) neutralizing the mixture with NH₄OH at elevated temperature; and
- (c) filtering the mixture.


7. The method of claim 1, further comprising recrystallizing Compound 1, comprising the steps of:

- (a) dissolving Compound 1 in a mixture of 1-propanol, water, and HCl;
- (b) neutralizing the mixture with an aqueous base at elevated temperature; and
- (c) filtering the mixture.

8. The method of claims 6 or 7, further comprising :

- (a) treating the Compound 1 solution with activated carbon;
- (b) removing the activated carbon by filtration; prior to neutralization.

9. The method of claims 6 or 7, further comprising
- (a) treating the Compound 1 solution with a metal scavenger at elevated temperature;
 - (b) removing the metal scavenger, prior to treating with activating carbon.
10. A crystal form of Compound 1, or a tautomer thereof:



Compound 1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.8, 12.0 and 17.9 °2θ.

11. A pharmaceutical composition comprising the crystal form of claim 10, or a pharmaceutically acceptable salt, tautomer, isotopologue or stereoisomer thereof, and one or more pharmaceutically acceptable excipients or carriers, each independently selected from carboxymethyl cellulose, cellulose, lactose, magnesium stearate, starch, and stearic acid.